Further clinical and epidemiological studies should assess the utility of concomitant pathological/genetic evaluation of NF-κB/p53-codon72 in surgically-removed gastric cancer specimens in order to predict the efficacy of post-operative 5-FU-based adjuvant chemotherapy. The gene discussed is TP53; the disease is gastric cancer.